Get the Stockscreener App
4.64
5.39%
-0.28
Atossa Therapeutics Inc stock is traded at $4.64, with a volume of 64,128.
It is down -5.39% in the last 24 hours and down -12.66% over the past month.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
See More
Previous Close:
$4.92
Open:
$4.92
24h Volume:
64,128
Relative Volume:
0.48
Market Cap:
$39.96M
Revenue:
-
Net Income/Loss:
$-26.91M
P/E Ratio:
-21.09
EPS:
-0.22
Net Cash Flow:
$-19.57M
1W Performance:
+4.14%
1M Performance:
-12.66%
6M Performance:
-60.62%
1Y Performance:
-58.25%
1-Day Range:
$4.52
$5.0099
1-Week Range:
$4.23
$5.12
52-Week Range:
$3.76
$19.35
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Name
Atossa Therapeutics Inc
Sector
Industry
Phone
206.588.0256
Address
10202 5TH AVENUE NE, SEATTLE, WA
Compare ATOS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
4.64 | 42.37M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.31 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
763.61 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
722.13 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.36 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.71 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-18 | Initiated | Maxim Group | Buy |
Atossa Therapeutics Inc Stock (ATOS) Latest News
Cash from financing activities of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Free cash flow of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Aug Fed Impact: Is Atossa Therapeutics Inc stock undervalued right nowQuarterly Profit Summary & Daily Growth Stock Investment Tips - baoquankhu1.vn
Total liabilities & shareholders' equities of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Atossa Therapeutics advances Z-endoxifen platform in oncology and DMD targeting molecular precision - Traders Union
ATOS PE Ratio & Valuation, Is ATOS Overvalued - Intellectia AI
Is Atossa Therapeutics Inc. stock influenced by commodity pricesJuly 2025 Recap & Daily Profit Focused Screening - mfd.ru
ATOS Should I Buy - Intellectia AI
ETF Watch: Is Chatham Lodging Trust a turnaround story2025 Market Trends & Weekly Chart Analysis and Guides - baoquankhu1.vn
ATOS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Atossa Therapeutics outlines Z-Endoxifen strategy for breast cancer prevention - Traders Union
Atossa Therapeutics Launches New $50 Million ATM Program - The Globe and Mail
Atos (ATOS) cuts $100M Jefferies ATM to $0, effective Feb 20, 2026 - Stock Titan
Atossa Therapeutics (NASDAQ: ATOS) launches $50M at-the-market stock offering - Stock Titan
Atossa Genetics Inc. (NASDAQ:ATOS) Receives $95.00 Consensus PT from Analysts - Defense World
Atossa Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk - The Globe and Mail
Net debt of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Patterns Watch: What is Atossa Therapeutics Incs TAM Total Addressable Market2025 Breakouts & Breakdowns & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Atossa Therapeutics, Inc. Balance Sheet – MUN:YAG - TradingView
Atossa Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Atossa Therapeutics to Participate in UCSF women health event - Traders Union
Basic earnings per share (basic EPS) of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Atossa Therapeutics: Key Developments and Upcoming Catalysts - AD HOC NEWS
Atossa Genetics Inc. (NASDAQ:ATOS) Short Interest Up 29.7% in January - Defense World
Is Atossa Therapeutics Inc. likely to announce a buybackJuly 2025 Rallies & Weekly Breakout Watchlists - mfd.ru
Is Atossa Therapeutics Inc. a speculative investmentWeekly Market Report & Free Technical Pattern Based Buy Signals - mfd.ru
Jobs Data: Is Atossa Therapeutics Incs growth already priced inJuly 2025 Price Swings & Stepwise Swing Trade Plans - baoquankhu1.vn
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook - The Malaysian Reserve
Atossa Therapeutics issues letter to shareholders highlighting 2025 accomplishments and 2026 outlook - marketscreener.com
Atossa Therapeutics Issues 2026 Outlook and Strategic Update - TipRanks
Atossa Therapeutics Issues Letter To Shareholders Highlighting 2025 Accomplishments And 2026 Outlook - TradingView
Atossa Therapeutics Issues 2026 Shareholder Letter Highlighting Key Developments - TradingView
Can Atossa Therapeutics Inc. be recession proofJuly 2025 Momentum & Community Consensus Trade Signals - mfd.ru
Atossa Therapeutics launches research program for oral therapy in DMD - Traders Union
We Think Atossa Therapeutics (NASDAQ:ATOS) Needs To Drive Business Growth Carefully - Yahoo Finance
Market Outlook: Is Atossa Therapeutics Inc part of any ETFWeekly Trading Summary & Weekly Momentum Picks - baoquankhu1.vn
Cash from financing activities of Atossa Therapeutics, Inc. – GETTEX:YAG - TradingView
Cost of goods sold of Atossa Therapeutics, Inc. – GETTEX:YAG - TradingView
Mammoth Energy sets March 6 call to review full-year 2025 results - Stock Titan
Atossa Therapeutics Maintains Strong Market Position for (Z)-End - GuruFocus
Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program - Sahm
ATOS stock tumbles 32% — here’s what retail investors think of the reverse stock split - MSN
Atossa Genetics (NASDAQ:ATOS) Sees Large Volume IncreaseWhat's Next? - MarketBeat
Atossa Therapeutics Inc Share Price USD0.18 - Hargreaves Lansdown
ATOS Stock Tumbles 32% — Here’s What Retail Investors Think Of The Reverse Stock Split - Asianet Newsable
Atossa Genetics (NASDAQ:ATOS) Sets New 1-Year LowWhat's Next? - MarketBeat
Atossa Therapeutics (ATOS) enters reverse-split Monday as Nasdaq compliance clock tightens - TechStock²
Atossa Genetics Inc. (NASDAQ:ATOS) Short Interest Up 56.4% in January - MarketBeat
Aug PreEarnings: How volatile is SKYQ stockWeekly Market Summary & Weekly Market Pulse Updates - baoquankhu1.vn
Atossa Genetics (NASDAQ:ATOS) Shares Set to Reverse Split on Monday, February 2nd - MarketBeat
Can Atossa Therapeutics Inc. lead its sector in growthGap Up & Verified Swing Trading Watchlist - mfd.ru
Atossa Therapeutics Inc Stock (ATOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atossa Therapeutics Inc Stock (ATOS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Remmel H. Lawrence | Director |
Mar 26 '25 |
Buy |
0.70 |
10,000 |
7,000 |
10,257 |
4.07%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):